AbbVie | ABBV - Operating Profit



AbbVie reported $5.72B in Operating Profit for its fiscal quarter ending in June of 2025.


Operating Profit Change Date
AbbVie USD 5.72B 1.98B Jun/2025
Abbott USD 2.07B 415M Jun/2025
ALKERMES USD 92.98M 79.19M Jun/2025
Amgen USD 2.66B 1.37B Jun/2025
AstraZeneca USD 3.51B 166M Jun/2025
Biogen USD 851.8M 540.6M Jun/2025
BioMarin Pharmaceutical USD 276.89M 52.99M Jun/2025
Bristol-Myers Squibb USD 3.77B 366M Jun/2025
Eisai JPY 20.74B 21.77B Jun/2025
Eli Lilly USD 7.02B 1.61B Jun/2025
Gilead Sciences USD 2.7B 467M Jun/2025
GlaxoSmithKline GBP 2.02B 193M Jun/2025
J&J USD 6.94B 6.69B Jun/2025
Medtronic USD 1.52B 81M Jul/2025
Merck USD 6.36B 494M Jun/2025
Neurocrine Biosciences USD 145.6M 121.9M Jun/2025
Novartis USD 4.86B 201M Jun/2025
Pacira USD 10.23M 8.24M Jun/2025
Perrigo USD 55.6M 23.8M Jun/2025
Pfizer USD 2.6B 1.06B Jun/2025
Regeneron Pharmaceuticals USD 1.08B 487.8M Jun/2025
Roche Holding CHF 4.39B 1.04B Dec/2024
Sanofi EUR 1.71B 573M Jun/2025
UCB EUR 1B 678M Dec/2024
Ultragenyx Pharmaceutical USD -193567000 50.63M Jun/2025
United Therapeutics USD 276.9M 105.9M Jun/2025
Vertex Pharmaceuticals USD 1.15B 123.1M Jun/2025
Zoetis USD 1.02B 205M Jun/2025